Compare MPC & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MPC | BDX |
|---|---|---|
| Founded | 1887 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.9B | 51.5B |
| IPO Year | 2011 | 1994 |
| Metric | MPC | BDX |
|---|---|---|
| Price | $226.81 | $163.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $204.15 | $189.60 |
| AVG Volume (30 Days) | 2.1M | ★ 2.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | 1.86% | ★ 2.56% |
| EPS Growth | ★ 31.15 | N/A |
| EPS | ★ 13.22 | 1.34 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.45 | $2.53 |
| P/E Ratio | ★ $16.25 | $122.76 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $115.10 | $161.75 |
| 52 Week High | $228.55 | $231.82 |
| Indicator | MPC | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 70.69 | 25.83 |
| Support Level | $174.22 | N/A |
| Resistance Level | N/A | $177.73 |
| Average True Range (ATR) | 7.75 | 4.15 |
| MACD | 1.36 | -1.02 |
| Stochastic Oscillator | 94.77 | 9.58 |
Marathon Petroleum is an independent refiner with 13 refineries in the mid continent, West Coast, and Gulf Coast of the United States with total throughput capacity of 3.0 million barrels per day. Its Dickinson, North Dakota, facility produces 184 million gallons a year of renewable diesel. Its Martinez, California, facility has the ability to produce 730 million gallons a year of renewable diesel. The firm also owns and operates midstream assets primarily through its listed master limited partnership, MPLX.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.